secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0000950170-24-029619
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA Enters Clinical Collaboration with Merck to Evaluate IDE161 + KEYTRUDA in Endometrial Cancer
--------------------------------------------------------------------------------

- Phase 1 trial will test IDE161 (PARG inhibitor) + KEYTRUDA in MSI-high and MSS endometrial cancer.
- Merck provides KEYTRUDA at no cost; IDEAYA sponsors the trial and pays study costs.
- Each party retains full commercial rights to its own compound as monotherapy or combination.
- IDE161 has FDA Fast-Track designation for BRCA1/2 ovarian and breast cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000095017024029619/0000950170-24-029619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000095017024029619/idya-20240308.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-029619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer